Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228537 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
A Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 20
- Study locations
NCT03228537: Active Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma, sponsored by National Cancer Institute (NCI).
NCT03228537 is a Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03228537, a Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.
Primary Outcome
The number of participants who received at least two cycles of the triplet neoadjuvant therapy getting at least one dose of maintenance therapy.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Pemetrexed Disodium
- PROCEDURE Extrapleural Pneumonectomy
- PROCEDURE Pleurectomy
Study Locations (20)
Colorado
- Penrose-Saint Francis Healthcare - Colorado Springs
- Rocky Mountain Cancer Centers-Penrose - Colorado Springs
- AdventHealth Porter - Denver
- CommonSpirit Cancer Center Mercy - Durango
- Mercy Medical Center - Durango
- Mountain Blue Cancer Care Center - Golden
- Rocky Mountain Cancer Centers-Lakewood - Lakewood
- Saint Anthony Hospital - Lakewood
- AdventHealth Littleton - Littleton
- Longmont United Hospital - Longmont
- Rocky Mountain Cancer Centers-Longmont - Longmont
- AdventHealth Parker - Parker
- Rocky Mountain Cancer Centers-Parker - Parker
- Saint Mary Corwin Medical Center - Pueblo
California
- PCR Oncology - Arroyo Grande
- City of Hope Comprehensive Cancer Center - Duarte
- University of California Davis Comprehensive Cancer Center - Sacramento
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Arkansas
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2026-09-18 |
| Phase | Phase 1 |
What the registry record for NCT03228537 still lists
NCT03228537 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 7 conditions, with Epithelioid Mesothelioma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT03228537 names 20 study sites across 4 states, led by Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03228537 about?
NCT03228537 is a clinical study titled "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma". This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune...
What is the current status of trial NCT03228537?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-07-16. Estimated completion is 2026-09-18.
What conditions does trial NCT03228537 study?
This clinical trial studies the following conditions: Epithelioid Mesothelioma, Biphasic Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7, Stage IA Pleural Malignant Mesothelioma AJCC v7, Stage IB Pleural Malignant Mesothelioma AJCC v7.
What interventions are being tested in trial NCT03228537?
The interventions under investigation include: Atezolizumab (DRUG), Cisplatin (DRUG), Pemetrexed Disodium (DRUG), Extrapleural Pneumonectomy (PROCEDURE), Pleurectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03228537?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03228537 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelioid Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03228537's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI